AstraZeneca’s Truqap edges closer to prostate cancer label expansion with Phase 3 win

After recently discontinuing R&D for Truqap in triple-negative breast cancer, AstraZeneca has some good news on its kinase inhibitor in a different indication. The UK drugmaker said Truqap succeeded in a late-stage study in prostate ...